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Abstract
Background: To understand the molecular basis of temporomandibular joint (TMJ) pathologies, we aimed to in-
vestigate the lubricin levels in the TMJ synovial fluid (SF) of patients with mild to severe internal derangements 
(IDs).
Material and Methods: A total, 34 joints were the study group. Only patients, with a Wilkes stage of III, IV and V 
were included, in this sample. Control group consisted of SF from eight joints, from patients undergoing to orthog-
natic surgery. Concentrations of lubricin in the SF from both samples were measured using ELISA system.
Results: The mean lubricin concentration was 7.029 ± 0.21 µg/mL in stage III patients; 5.64 ± 0.10 µg/mL in stage 
IV patients, and 4.78 ± 0.11 µg/mL in stage V patients. The lubricin levels from stage IV and stage V patients dif-
fered significantly (P ≤ 0.001) from those of control subjects. Lubricin levels were inversely correlated with age 
and to VAS score.
Conclusions: The results of this cross-sectional study highlight the relationship between disease severity and the 
levels of lubricin in TMJ SF. Our findings suggest that novel biotherapeutic approaches, including the administra-
tion of recombinant lubricin in the joint cavity, for the treatment of TMJ diseases can be developed. 
Key words: Lubricin, TMJ, derangements, synovial fluid.
Leonardi R, Perrotta RE, Almeida LE, Loreto C, Musumeci G. Lu-
bricin in synovial fluid of mild and severe temporomandibular joint 
internal derangements. Med Oral Patol Oral Cir Bucal. 2016 Nov 1;21 
(6):e793-9.
 http://www.medicinaoral.com/medoralfree01/v21i6/medoralv21i6p793.pdf
Article Number: 21145          http://www.medicinaoral.com/
© Medicina Oral S. L. C.I.F. B 96689336 - pISSN 1698-4447 - eISSN: 1698-6946
eMail:  medicina@medicinaoral.com 
Indexed in: 
Science Citation Index Expanded
Journal Citation Reports
Index Medicus, MEDLINE, PubMed
Scopus, Embase and Emcare 
Indice Médico Español
doi:10.4317/medoral.21145
http://dx.doi.org/doi:10.4317/medoral.21145
Med Oral Patol Oral Cir Bucal. 2016 Nov 1;21 (6):e793-9.                                                                                                                                                                                  lubricin in synovial fluid
e794
Introduction
Temporomandibular disorders (TMDs) are conditions 
that affect the temporomandibular joint (TMJ) and re-
lated musculoskeletal structures. Normally, these disor-
ders are divided into classical myofascial pain, internal 
derangement (ID), and osteoarthrosis (OA) (1).
Clinically speaking, mild TMJ-ID is characterized by 
disc displacement, with or without osseous remodeling, 
whereas severe derangement includes disc or attach-
ment perforations, osseous remodeling, and osteoar-
thritic changes. OA is a degenerative change in the TMJ 
that alters its physical and functional properties, the dis-
order leads to the reversible, and subsequently irrevers-
ible, inability of the TMJ to withstand loading stress.
Wilkes proposed the classification, which is commonly 
used for describing the severity of TMJ diseases (Table 
1) but is also extremely useful for diagnosis (2). 
Stage I Early
Patients with painless clicking, no restricted motion, slightly forwarded disc 
(reducing), and normal osseous contours
Stage II Early/
Intermediate
Patients with occasional painful clicking, intermittent locking, headache, slightly 
forwarded disc  (reducing), with early disc deformity, and normal osseous con-
tours
Stage III
Intermediate
Patients with frequent pain, joint tenderness, locking, headache, restricted mo-
tion, painful chewing (characteristics), anterior disc displacement, moderate to 
marked disc thickening, and normal osseous contours
Stage IV
Intermediate/
Late
Patients with chronic pain, headache, restricted motion, anterior disc displace-
ment, marked disk thickening, and abnormal bone contours
Stage V Late
Patients with variable pain, joint crepitus, anterior disc displacement with disc 
perforation and gross deformity, and degenerative osseous changes
Table 1. Wilkes classification of TMJ diseases.
Wilkes’s staging is based on the progression of the gross 
pathology of ID and OA in the joint. The Wilkes clas-
sification consists of five stages based on clinical, radio-
logic and intraoperative findings; it varies from a slight 
forward displacement with symptom-free normal joints 
to degenerative arthritic changes with severe clinical 
symptoms (3). The chronic degenerative tissue changes 
whereas OA experienced in TMJ disorders may affect 
articular cartilage and adjacent joint connective tissue 
responses, including the articular capsule and liga-
ments, synovial membrane, and the articular bone. 
Specific circumstances have been linked to the develop-
ment of TMJ-OA, including impairment of the synovial 
fluid (SF) (2,4). Indeed, compromised lubrication in the 
TMJ is associated with altered frictional properties and 
surface wear of the condylar cartilage, which is accom-
panied by the release of pro-inflammatory and matrix 
degradation mediators under mechanical loading condi-
tions (5). Several molecules that are present in the SF con-
tribute to joint lubrication, particularly boundary lubrica-
tion; one such molecule is lubricin (4,6). A longstanding 
TMJ disc injury affects lubricin expression in the TMJ 
disc tissue (7). In an investigation of lubricin levels in 
the SF of patients with TMJ disorders, lubricin was down 
regulated in patients affected by OA versus patients af-
fected by displaced disc with or without reduction (8). 
However, any correlation of lubricin levels with Wilkes’s 
stages, signs and/or symptoms was not provided. 
In order to gain a better understanding of the  degenera-
tive change mechanism and the molecular basis of OA 
etiopathogenesis,  we decided to use this study to  inves-
tigate the lubricin levels in the TMJ SF of patients with 
mild to severe ID. The observed lubricin concentrations 
were, therefore, correlated with the Wilkes stages, pa-
tient ages, visual analog scale (VAS) scores, and maxi-
mum interincisal mouth (MIO) opening measurements.
Material and Methods
- Subjects
The study subjects were selected from a consecutive 
series of patients who attended the Orofacial Pain and 
TMD Clinic in the Department of Oral and Maxillo-
facial Surgery at the Pontifical Catholic University of 
Paraná, Brazil, from February 2009 to May 2013.
This cross-sectional study was approved by the Ethical 
Committee on Research at Pontifical Catholic Univer-
sity of Paraná, according to Resolution 196/96 of the 
National Health Council, and it was approved under 
registration number 104. A signed informed consent 
form was also obtained from each patient before col-
lecting  the TMJ SF.
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Clinical TMD was diagnosed according to the clinical 
diagnostic criteria published by Truelove et al. (9). All 
patients were subject to a standard pre-operative ex-
amination by the same clinician and were then asked to 
fill in a VAS to assess pain with endpoint scores going 
from 0 (no pain) to 10 (worst pain ever experienced). 
The MIO opening was measured with a ruler to the 
nearest millimeter. Joint sounds were evaluated by us-
ing finger palpation and a stethoscope. Joint and muscle 
tenderness were also assessed by finger palpation. The 
diagnosis was based on the clinical status but was also 
supported by the findings from computed tomography, 
magnetic resonance imaging, or both (Fig. 1). Following 
these evaluations, the patients were classified according 
to their appropriate Wilkes stage (2).
The inclusion criteria were a diagnosis of Wilkes stage 
(2) III, IV, or V. The exclusion criteria were as follows: 
a diagnosis of Wilkes stage I or II, systemic arthropa-
thy, use of nonsteroidal anti-inflammatory drugs, and/
or history of trauma. 
A total number of 34 joints from 32 patients (5 males 
and 27 females; age range: 21-62 years; mean age: 34 ± 
11.04) were included in the study group. Two patients 
included in this study group had bilateral TMJ involve-
ment. The preoperative clinical signs and symptoms of 
the patients, defined according to the Wilkes stages, are 
shown in table 2. The mean duration of these symptoms 
was 4 years (range: 0.7-18 years).
The control group consisted of SF from eight joints 
from eight patients (two males and six females; age 
range: 28-54 years, (mean age: 42.3 ± 9,5) without signs 
or symptoms of TMJ disorders. These control patients 
were volunteers who were undergoing orthognathic sur-
gery and had agreed to participate in the study. 
- Collection of the TMJ SF 
Prior to arthrocentesis (under local anesthesia), the SF 
samples were collected from the superior joint cavity 
using diluted aspiration as previously described. Brief-
ly, the skin surface was disinfected and SF was aspi-
rated from the affected side of the patients with TMJ 
disorder and the right-sided TMJ of the control subjects. 
Physiological saline (1.0 mL) was injected into the up-
per joint cavity using a 21-gauge hypodermic needle. 
The SF was collected using the push-and-pull method, 
which involves repeating the aspiration and injection 
approximately five times. Afterwards, the collected SF 
was centrifuged (4°C, 10 min, 1500 ×g) prior to measur-
ing the  lubricin concentrations. Only the supernatant 
was separated and stored in a deep freezer (-80°C). The 
total amount of protein from each sample was deter-
mined by measuring the optical density at 280 nm, with 
bovine serum albumin used as the standard. 
- Enzyme-linked immunosorbent assay (ELISA) analy-
sis of lubricin in the SF
Concentrations of lubricin in the SF were measured 
using a commercially available ELISA system (Pierce 
Biotechnology, Rockford, IL, USA) as previously de-
scribed, (10,11) following the manufacturer’s instruc-
tions for the quantitative determination of lubricin. The 
assay sensitivity of lubricin was 3.25 pg/mL. Concen-
trations of lubricin less than minimal sensitivity were 
considered as 0 pg/mL. The level of lubricin was de-
Fig. 1. MRI findings of Anterior disc displacement without reduction.
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fined as its concentration per milligram of total protein 
in the SF.
- Statistical analysis
Mean values and standard deviations were calculated 
for lubricin levels in TMJ SF in each subgroup of the 
sample (i.e., Wilkes stages III, IV, and V). A Shapiro–
Wilk test was used to test for normality. Data had a 
non-parametric distribution, therefore, Mann–Whitney 
U tests were used to evaluate any statistical differences 
among the lubricin levels of the three Wilkes stage sub-
groups and the control group. 
A non-parametric Spearman’s rank correlation test (rho) 
was used to obtain the correlation coefficient from cor-
relations between lubricin levels and patient ages, VAS 
!
Wilkes 
Classification 
Age (yrs) Gender Disease side 
Lubricin 
(pg/ml) 
VAS MIO 
Stage III 26 F L 6.9 76 24 
Stage III 32 F R 6.9 68 21 
Stage III 21 F R 7.2 72 14 
Stage III 34 F L 7.4 68 7 
Stage III 24 F R 6.9 75 18 
Stage III 27 F R 7.1 69 11 
Stage III 31 F L 6.8 74 9 
Stage IV 60 F R 6.2 70 14 
Stage IV 32 M R 5.6 73 22 
Stage IV 27 F R 6.1 78 12 
Stage IV 45 F L 5.4 79 26 
Stage IV 22 F R 6 83 14 
Stage IV 25 F L 5.7 68 11 
Stage IV 32 M R 5.6 74 5 
Stage IV 41 F L 5.2 74 8 
Stage IV 26 F L 5.2 79 21 
Stage IV 33 F R 5.6 82 18 
Stage IV 28 F R 5.5 75 14 
Stage V 59 F L 4.2 84 11 
Stage V 34 F R 4.9 89 20 
Stage V 42 M L 5.4 78 6 
Stage V 35 F R 5.2 91 13 
Stage V 35 F R 4.4 91 13 
Stage V 26 F R 5 86 24 
Stage V 35 F R 4.8 88 18 
Stage V 46 F R 5.6 77 5 
Stage V 32 M L 5.2 80 9 
Stage V 32 M R 5.1 80 9 
Stage V 24 F L 4.3 86 26 
Stage V 35 F L 4.8 87 24 
Stage V 62 F R 4.5 81 22 
Stage V 29 F R 4.9 83 15 
Stage V 40 M L 4.1 89 17 
Stage V 58 F R 4.2 88 19 
Table  2. Patient background data.  Abbreviations: F: Female; M: Male; MIO: Maximum interincisal opening; visual analog 
scale (0-100). 
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scores, and MIO. P-values ≤ 0.05 were considered statis-
tically significant. All data were analyzed using the SPSS 
program (SPSS release 16.0; SPSS, Chicago, IL, USA).
Results
The distribution of patients according to the Wilkes 
classification was as follows: 
seven patients were stage III, 11 patients were stage IV, 
and 14 patients were stage V (Table 2). 
The SF lubricin concentration obtained from normal 
joints was 7.425 ± 0.34 µg/mL. On the contrary, in the 
study group the lubricin levels progressively decreased 
as the Wilkes stage became more severe. Specifically, 
the mean lubricin concentration was 7.029 ± 0.21 µg/
mL in stage III patients; 5.64 ± 0.10 µg/mL, in stage 
IV patients, and 4.78 ± 0.11 µg/mL in stage V patients. 
The lubricin levels from stage IV and stage V patients 
differed significantly (P ≤ 0.001) from those of control 
subjects, (Table 3). 
The lubricin levels were inversely correlated with age 
(rho = −0.445; P ≤ 0.008) (Fig. 2) and to VAS score (rho 
= −0.823; P ≤ 0.009) (Fig. 3); on the other hand, there 
was no statistically significant correlation between the 
lubricin levels and MIO. 
control Stage III Stage IV Stage V
control - N.S. P≤0.001 P≤0.001
Stage III N.S - P≤0.001 P≤0.001
Stage IV
           P≤0.001
P≤0.001 - P≤0.001
Stage V P≤0.001 P≤0.001 P≤0.001 -
Table 3. Statistical differences and levels of significance, among the lubricin concentrations in the three Wilkes stage 
subgroups and the control group according to Mann–Whitney U tests.
Fig. 2. Correlation analysis of lubricin concentrations and patient age.
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Discussion
Articular cartilage functions as a surface that allows 
joint movement under conditions of extremely low fric-
tion. Hyaluronic acid (HA) and lubricin are two major 
joint lubricants that protect surfaces from wear (12). 
The mechanically trapped HA–lubricin complex acts 
as an effective chemically bound lubricant that slightly 
reduces friction forces but more importantly eliminates 
wear damage to the cartilage surfaces. Thus, the lubri-
cation system as a whole requires both HA and lubricin 
to function optimally (11-13). Lubricin is a proteoglycan 
that is specifically synthesized and expressed by articu-
lar chondrocytes of the superficial zone (14). 
Lubricin may be degraded and its synthesis may be re-
duced due to a loss of joint lining cells (the major lu-
bricin producers) or inhibition of lubricin synthesis by 
inflammatory cytokines. Indeed, numerous cytokines 
and growth factors are reportedly involved in the regu-
lation of lubricin expression. For example, TGF-β1, an 
anabolic factor, up-regulates the synthesis and surface 
localization of lubricin, whereas IL-1β or TNF-α down-
regulates the production of lubricin (15,16). 
It has also been suggested that the altered joint mechan-
ics in knee injuries can lead to decreased lubricin ex-
pression in the superficial layer as well as decreased lu-
bricin coating of the surface of articular cartilage. These 
effects are significant risk factors for the development 
of secondary OA (17,18). In fact, following a traumatic 
knee injury, articular cartilage surfaces are predisposed 
to wear-induced damage because of the resultant chang-
es in joint lubricating mechanisms, which are mediated 
by lubricin catabolism, and down-regulation due to el-
evated inflammatory cytokines levels (17). Therefore, 
lubricin is deficient in arthritic joints (11,19,20). 
As far as TMJ is concerned, some studies on animals 
have highlighted the essential role of lubricin in the 
maintenance of TMJ integrity and in the earlier onset 
of TMJ-OA (21,22). However, very few studies have in-
vestigated lubricin expression in human TMJ fluid and 
tissues (7,8). From these few investigations, it appears 
that lubricin was down-regulated in diseased TMJ disc 
tissue from patients with IDs (7). Moreover, lubricin 
concentrations in SF were apparently lower in patients 
with OA but not in patients with IDs (8). 
Findings from our study are in agreement with this previ-
ous data.  We also demonstrated that the patients’ lubri-
cin levels progressively decreased as their Wilkes stage 
became more severe and that the lubricin levels were in-
versely correlated with patient age and VAS (but not with 
MIO). Our results are corroborated by previous findings 
obtained in studies from joints other than the TMJ, these 
studies demonstrated that Lubricin/PRG4 gene expres-
sion is affected by aging, which may lead to altered me-
chanical joint function in elderly subjects (23). 
The discovery that lubricin levels are inversely corre-
lated with pain (i.e., with VAS scores) is a novel result 
in the present study. It could be argued that this latter 
result could be somehow related to the release of pro-
inflammatory and matrix degradation mediators in the 
SF of patients with TMJ disease. 
Regarding this, previous studies reported that in TMJ 
SF, the TNF-α levels increased in patients with IDs as 
Fig. 3. Correlation analysis of lubricin concentrations and VAS. 
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the stage of the disease progresses, pain levels (VAS 
scores) increased too. Thus, AA (24) concluded that 
TNF-α may contribute to the pathogenesis of TMJ car-
tilage and bone degeneration. In addition, TNF-α induc-
es the production of other pro-inflammatory cytokines 
such as IL-1, IL-6, and IL-8 (25), which in turn deter-
mines the down-regulation of lubricin (17). 
Further evidence is provided from another study which 
demonstrated that under mechanical loading condi-
tions, there is a release of pro-inflammatory and matrix 
degradation mediators which are associated with al-
tered frictional properties and surface wear of condylar 
cartilage (5). 
Thus, given these previous findings and our present 
data, it can be hypothesized that in the TMJ, similar to 
other joints, both altered loading and inflammation can 
lead to decreased lubricin levels, which in turn play a 
role in the onset of degenerative changes in joints.
In conclusion, the results of this cross-sectional study 
highlight the relationship  between disease severity and 
the levels of lubricin in TMJ SF.  Significantly, our  find-
ings suggest that novel biotherapeutic approaches for 
the treatment of OA,  including the administration of 
recombinant lubricin in the joint cavity, could be devel-
oped in future for the prevention of cartilage degenera-
tion.
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